Although a tumor-specific marker for prostate cancer is not available as yet, the advent of PSA and its derivatives, like PSA-IgM, as well as other markers, like PCA-3, has been investigated with the aim to support the early diagnosis of prostate cancer (79–81). Here, PCA3 is linked to prostate carcinoma.